{"nct_id":"NCT01356849","title":"Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor","status":"COMPLETED","status_verified_date":"2013-08","start_date":"2011-04","start_date_type":null,"primary_completion_date":"2012-08","primary_completion_date_type":"ACTUAL","completion_date":"2012-08","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["ABBV"]}